Guarantor Financial Information (Tables)

9 Months Ended

Sep. 30, 2018

Condensed Financial Information Disclosure [Abstract]



Condensed Consolidating Statements of Operations
(Unaudited, In millions)
Three months ended September 30, 2018	Shire plc (Parent Guarantor)			SAIIDAC (SAIIDAC Notes Subsidiary Issuer)			Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)			Non-Guarantor Non-Issuer Subsidiaries			Non-Guarantor Subsidiaries of Baxalta Notes			Eliminations			Consolidated
Revenues:
Product sales	$	—		$	—		$	—		$	3,752.8		$	3,752.8		$	—		$	3,752.8
Royalties and other revenues	—			—			—			118.9			118.9			—			118.9
Total revenues	—			—			—			3,871.7			3,871.7			—			3,871.7
Costs and expenses:
Cost of sales	—			—			—			1,157.6			1,157.6			—			1,157.6
Research and development	—			—			—			407.2			407.2			—			407.2
Selling, general and administrative	(14.5		)	—			—			851.3			851.3			—			836.8
Amortization of acquired intangible assets	—			—			—			433.7			433.7			—			433.7
Integration and acquisition costs	45.0			—			5.3			42.7			42.7			—			93.0
Reorganization costs	—			—			—			254.8			254.8			—			254.8
Gain on sale of Oncology franchise and product rights	—			—			—			(267.2		)	(267.2		)	—			(267.2		)
Total operating expenses	30.5			—			5.3			2,880.1			2,880.1			—			2,915.9

Operating income/(loss) from continuing operations	(30.5		)	—			(5.3		)	991.6			991.6			—			955.8

Interest income/(expense), net	(43.7		)	5.6			(37.1		)	(48.7		)	(43.1		)	—			(123.9		)
Other income/(expense), net	0.2			—			(24.8		)	(71.5		)	(71.5		)	—			(96.1		)
Total other income/(expense), net	(43.5		)	5.6			(61.9		)	(120.2		)	(114.6		)	—			(220.0		)

Income/(loss) from continuing operations before income taxes and equity in earnings/(losses) of equity method investees	(74.0		)	5.6			(67.2		)	871.4			877.0			—			735.8
Income taxes	0.2			(2.4		)	15.2			(216.3		)	(218.7		)	—			(203.3		)
Equity in earnings/(losses) of equity method investees, net of taxes	611.0			—			(74.2		)	4.7			4.7			(536.8		)	4.7
Income/(loss) from continuing operations, net of taxes	537.2			3.2			(126.2		)	659.8			663.0			(536.8		)	537.2
Net income/(loss)	537.2			3.2			(126.2		)	659.8			663.0			(536.8		)	537.2
Comprehensive income/(loss)	$	436.0		$	3.2		$	(220.3	)	$	558.6		$	561.8		$	(341.5	)	$	436.0



Condensed Consolidating Statements of Operations
(Unaudited, In millions)
Nine months ended September 30, 2018	Shire plc (Parent Guarantor)			SAIIDAC (SAIIDAC Notes Subsidiary Issuer)			Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)			Non-Guarantor Non-Issuer Subsidiaries			Non-Guarantor Subsidiaries of Baxalta Notes			Eliminations			Consolidated
Revenues:
Product sales	$	—		$	—		$	—		$	11,198.5		$	11,198.5		$	—		$	11,198.5
Royalties and other revenues	—			—			—			358.4			358.4			—			358.4
Total revenues	—			—			—			11,556.9			11,556.9			—			11,556.9
Costs and expenses:
Cost of sales	—			—			—			3,398.3			3,398.3			—			3,398.3
Research and development	—			—			—			1,240.0			1,240.0			—			1,240.0
Selling, general and administrative	76.4			—			7.2			2,465.7			2,465.7			—			2,549.3
Amortization of acquired intangible assets	—			—			—			1,375.3			1,375.3			—			1,375.3
Integration and acquisition costs	142.7			—			7.4			361.9			361.9			—			512.0
Reorganization costs	—			—			—			268.9			268.9			—			268.9
Gain on sale of Oncology franchise and product rights	—			—			—			(267.2		)	(267.2		)	—			(267.2		)
Total operating expenses	219.1			—			14.6			8,842.9			8,842.9			—			9,076.6

Operating income/(loss) from continuing operations	(219.1		)	—			(14.6		)	2,714.0			2,714.0			—			2,480.3

Interest income/(expense), net	(110.4		)	(2.2		)	(91.6		)	(169.1		)	(171.3		)	—			(373.3		)
Other income/(expense), net	—			—			(23.9		)	(20.0		)	(20.0		)	—			(43.9		)
Total other income/(expense), net	(110.4		)	(2.2		)	(115.5		)	(189.1		)	(191.3		)	—			(417.2		)

Income/(loss) from continuing operations before income taxes and equity in earnings/(losses) of equity method investees	(329.5		)	(2.2		)	(130.1		)	2,524.9			2,522.7			—			2,063.1
Income taxes	17.4			0.6			28.4			(417.4		)	(416.8		)	—			(371.0		)
Equity in earnings/(losses) of equity method investees, net of taxes	2,015.4			—			243.2			11.2			11.2			(2,258.6		)	11.2
Income/(loss) from continuing operations, net of taxes	1,703.3			(1.6		)	141.5			2,118.7			2,117.1			(2,258.6		)	1,703.3
Net income/(loss)	1,703.3			(1.6		)	141.5			2,118.7			2,117.1			(2,258.6		)	1,703.3
Comprehensive income/(loss)	$	954.7		$	(1.6	)	$	(538.7	)	$	1,370.1		$	1,368.5		$	(829.8	)	$	954.7



Condensed Consolidating Statements of Operations
(Unaudited, In millions)
Three months ended September 30, 2017	Shire plc (Parent Guarantor)			SAIIDAC (SAIIDAC Notes Subsidiary Issuer)		Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)			Non-Guarantor Non-Issuer Subsidiaries			Non-Guarantor Subsidiaries of Baxalta Notes			Eliminations			Consolidated
Revenues:
Product sales	$	—		$	—	$	—		$	3,533.8		$	3,533.8		$	—		$	3,533.8
Royalties and other revenues	—			—		—			163.8			163.8			—			163.8
Total revenues	—			—		—			3,697.6			3,697.6			—			3,697.6
Costs and expenses:
Cost of sales	—			—		—			1,001.4			1,001.4			—			1,001.4
Research and development	—			—		—			402.8			402.8			—			402.8
Selling, general and administrative	6.1			—		4.0			849.6			849.6			—			859.7
Amortization of acquired intangible assets	—			—		—			482.4			482.4			—			482.4
Integration and acquisition costs	—			—		9.2			227.8			227.8			—			237.0
Reorganization costs	—			—		—			5.4			5.4			—			5.4
Loss on sale of product rights	—			—		—			0.3			0.3			—			0.3
Total operating expenses	6.1			—		13.2			2,969.7			2,969.7			—			2,989.0

Operating income/(loss) from continuing operations	(6.1		)	—		(13.2		)	727.9			727.9			—			708.6

Interest income/(expense), net	(48.0		)	3.0		(23.6		)	(71.7		)	(68.7		)	—			(140.3		)
Other income/(expense), net	—			—		4.4			(4.6		)	(4.6		)	—			(0.2		)
Total other income/(expense), net	(48.0		)	3.0		(19.2		)	(76.3		)	(73.3		)	—			(140.5		)

Income/(loss) from continuing operations before income taxes and equity in earnings/(losses) of equity method investees	(54.1		)	3.0		(32.4		)	651.6			654.6			—			568.1
Income taxes	0.9			0.6		(8.9		)	(6.1		)	(5.5		)	—			(13.5		)
Equity in earnings/(losses) of equity method investees, net of taxes	604.0			—		(79.8		)	(3.3		)	(3.3		)	(524.3		)	(3.4		)
Income/(loss) from continuing operations, net of taxes	550.8			3.6		(121.1		)	642.2			645.8			(524.3		)	551.2
Loss from discontinued operations, net of taxes	—			—		—			(0.4		)	(0.4		)	—			(0.4		)
Net income/(loss)	550.8			3.6		(121.1		)	641.8			645.4			(524.3		)	550.8
Comprehensive income/(loss)	$	1,319.8		$	3.6	$	581.0		$	1,411.2		$	1,414.8		$	(1,995.8	)	$	1,319.8



Condensed Consolidating Statements of Operations
(Unaudited, In millions)
Nine months ended September 30, 2017	Shire plc (Parent Guarantor)			SAIIDAC (SAIIDAC Notes Subsidiary Issuer)			Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)			Non-Guarantor Non-Issuer Subsidiaries			Non-Guarantor Subsidiaries of Baxalta Notes			Eliminations			Consolidated
Revenues:
Product sales	$	—		$	—		$	—		$	10,537.9		$	10,537.9		$	—		$	10,537.9
Royalties and other revenues	—			—			—			477.8			477.8			—			477.8
Total revenues	—			—			—			11,015.7			11,015.7			—			11,015.7
Costs and expenses:
Cost of sales	—			—			—			3,437.3			3,437.3			—			3,437.3
Research and development	—			—			—			1,324.5			1,324.5			—			1,324.5
Selling, general and administrative	24.2			—			15.3			2,608.2			2,608.2			—			2,647.7
Amortization of acquired intangible assets	—			—			—			1,280.5			1,280.5			—			1,280.5
Integration and acquisition costs	164.7			—			52.3			479.7			479.7			—			696.7
Reorganization costs	—			—			—			24.5			24.5			—			24.5
Loss on sale of product rights	—			—			—			(0.4		)	(0.4		)	—			(0.4		)
Total operating expenses	188.9			—			67.6			9,154.3			9,154.3			—			9,410.8

Operating income/(loss) from continuing operations	(188.9		)	—			(67.6		)	1,861.4			1,861.4			—			1,604.9

Interest income/(expense), net	(109.1		)	14.5			(66.5		)	(258.6		)	(244.1		)	—			(419.7		)
Other income/(expense), net	1.8			—			4.3			0.7			0.7			—			6.8
Total other income/(expense), net	(107.3		)	14.5			(62.2		)	(257.9		)	(243.4		)	—			(412.9		)

Income/(loss) from continuing operations before income taxes and equity in earnings/(losses) of equity method investees	(296.2		)	14.5			(129.8		)	1,603.5			1,618.0			—			1,192.0
Income taxes	1.7			(3.6		)	(45.0		)	2.3			(1.3		)	—			(44.6		)
Equity in earnings/(losses) of equity method investees, net of taxes	1,460.6			—			(119.7		)	0.1			0.1			(1,340.9		)	0.1
Income/(loss) from continuing operations, net of taxes	1,166.1			10.9			(294.5		)	1,605.9			1,616.8			(1,340.9		)	1,147.5
Gain from discontinued operations, net of taxes	—			—			—			18.6			18.6			—			18.6
Net income/(loss)	1,166.1			10.9			(294.5		)	1,624.5			1,635.4			(1,340.9		)	1,166.1
Comprehensive income/(loss)	$	3,632.8		$	10.9		$	2,031.5		$	4,088.2		$	4,099.1		$	(6,130.6	)	$	3,632.8

Condensed Balance Sheet



Condensed Consolidating Balance Sheets
(Unaudited, In millions)
As of September 30, 2018	Shire plc (Parent Guarantor)		SAIIDAC (SAIIDAC Notes Subsidiary Issuer)		Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)		Non-Guarantor Non-Issuer Subsidiaries		Non-Guarantor Subsidiaries of Baxalta Notes		Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	—	$	—	$	193.2	$	193.2	$	—		$	193.2
Restricted cash	—		—		—		39.9		39.9		—			39.9
Accounts receivable, net	—		—		—		3,207.4		3,207.4		—			3,207.4
Inventories	—		—		—		3,458.7		3,458.7		—			3,458.7
Other current assets	—		1.5		81.2		817.4		818.9		—			900.1
Intercompany receivables	—		41.0		—		7,811.8		7,852.8		(7,852.8		)	—
Short term intercompany loan receivable	—		4,210.3		—		—		4,210.3		(4,210.3		)	—
Total current assets	—		4,252.8		81.2		15,528.4		19,781.2		(12,063.1		)	7,799.3
Non-current assets:
Investments	44,695.6		—		38,547.8		13,312.3		13,312.3		(96,085.0		)	470.7
Property, plant and equipment (PP&E), net	—		—		4.6		6,448.4		6,448.4		—			6,453.0
Goodwill	—		—		—		19,095.0		19,095.0		—			19,095.0
Intangible assets, net	—		—		—		29,625.4		29,625.4		—			29,625.4
Deferred tax asset	—		—		304.1		151.2		151.2		(304.1		)	151.2
Long term intercompany loan receivable	—		8,763.6		3,507.0		—		8,763.6		(12,270.6		)	—
Other non-current assets	—		1.9		—		169.4		171.3		—			171.3
Total assets	$	44,695.6	$	13,018.3	$	42,444.7	$	84,330.1	$	97,348.4	$	(120,722.8	)	$	63,765.9
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	6.4	$	8.0	$	33.6	$	3,977.1	$	3,985.1	$	—		$	4,025.1
Short term borrowings and capital leases	—		4,210.3		—		38.4		4,248.7		—			4,248.7
Intercompany payables	3,612.5		—		4,240.3		—		—		(7,852.8		)	—
Short term intercompany loan payable	—		—		—		4,210.3		4,210.3		(4,210.3		)	—
Other current liabilities	—		—		3.8		234.0		234.0		—			237.8
Total current liabilities	3,618.9		4,218.3		4,277.7		8,459.8		12,678.1		(12,063.1		)	8,511.6
Long term borrowings and capital leases	—		8,763.6		1,939.9		394.5		9,158.1		—			11,098.0
Deferred tax liability	—		—		—		4,875.3		4,875.3		(304.1		)	4,571.2
Long term intercompany loan payable	3,786.5		—		—		8,484.1		8,484.1		(12,270.6		)	—
Other non-current liabilities	—		—		60.3		2,234.6		2,234.6		—			2,294.9
Total liabilities	7,405.4		12,981.9		6,277.9		24,448.3		37,430.2		(24,637.8		)	26,475.7
Total equity	37,290.2		36.4		36,166.8		59,881.8		59,918.2		(96,085.0		)	37,290.2
Total liabilities and equity	$	44,695.6	$	13,018.3	$	42,444.7	$	84,330.1	$	97,348.4	$	(120,722.8	)	$	63,765.9



Condensed Consolidating Balance Sheets
(Unaudited, In millions)
As of December 31, 2017	Shire plc (Parent Guarantor)		SAIIDAC (SAIIDAC Notes Subsidiary Issuer)		Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)		Non-Guarantor Non-Issuer Subsidiaries		Non-Guarantor Subsidiaries of Baxalta Notes		Eliminations			Consolidated
ASSETS
Current assets:
Cash and cash equivalents	$	—	$	—	$	0.5	$	471.9	$	471.9	$	—		$	472.4
Restricted cash	—		—		—		39.4		39.4		—			39.4
Accounts receivable, net	—		—		—		3,009.8		3,009.8		—			3,009.8
Inventories	—		—		—		3,291.5		3,291.5		—			3,291.5
Other current assets	—		1.6		95.2		698.5		700.1		—			795.3
Intercompany receivables	—		120.2		—		4,682.3		4,802.5		(4,802.5		)	—
Short term intercompany loan receivable	—		2,006.3		—		—		2,006.3		(2,006.3		)	—
Total current assets	—		2,128.1		95.7		12,193.4		14,321.5		(6,808.8		)	7,608.4
Non-current assets:
Investments	43,204.3		—		38,924.6		13,059.4		13,059.4		(94,947.2		)	241.1
Property, plant and equipment (PP&E), net	—		—		7.6		6,627.8		6,627.8		—			6,635.4
Goodwill	—		—		—		19,831.7		19,831.7		—			19,831.7
Intangible assets, net	—		—		—		33,046.1		33,046.1		—			33,046.1
Deferred tax asset	—		—		304.1		188.8		188.8		(304.1		)	188.8
Long term intercompany loan receivable	—		12,050.2		1,609.3		—		12,050.2		(13,659.5		)	—
Other non-current assets	—		2.8		—		202.6		205.4		—			205.4
Total assets	$	43,204.3	$	14,181.1	$	40,941.3	$	85,149.8	$	99,330.9	$	(115,719.6	)	$	67,756.9
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	0.2	$	85.9	$	18.1	$	4,080.3	$	4,166.2	$	—		$	4,184.5
Short term borrowings and capital leases	—		2,006.3		748.8		33.6		2,039.9		—			2,788.7
Intercompany payables	3,585.3		—		1,217.2		—		—		(4,802.5		)	—
Short term intercompany loan payable	—		—		—		2,006.3		2,006.3		(2,006.3		)	—
Other current liabilities	573.5		—		10.7		324.6		324.6		—			908.8
Total current liabilities	4,159.0		2,092.2		1,994.8		6,444.8		8,537.0		(6,808.8		)	7,882.0
Long term borrowings and capital leases	—		12,050.2		4,308.9		393.3		12,443.5		—			16,752.4
Deferred tax liability	—		—		—		5,052.3		5,052.3		(304.1		)	4,748.2
Long term intercompany loan payable	2,868.9		—		—		10,790.6		10,790.6		(13,659.5		)	—
Other non-current liabilities	—		—		70.0		2,127.9		2,127.9		—			2,197.9
Total liabilities	7,027.9		14,142.4		6,373.7		24,808.9		38,951.3		(20,772.4		)	31,580.5
Total equity	36,176.4		38.7		34,567.6		60,340.9		60,379.6		(94,947.2		)	36,176.4
Total liabilities and equity	$	43,204.3	$	14,181.1	$	40,941.3	$	85,149.8	$	99,330.9	$	(115,719.6	)	$	67,756.9

Condensed Cash Flow Statement



Condensed Consolidating Statements of Cash Flows
(Unaudited, In millions)
Nine months ended September 30, 2018	Shire plc (Parent Guarantor)			SAIIDAC (SAIIDAC Notes Subsidiary Issuer)			Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)			Non-Guarantor Non-Issuer Subsidiaries			Non-Guarantor Subsidiaries of Baxalta Notes			Eliminations			Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided by/(used in) operating activities	$	(251.2	)	$	(17.4	)	$	264.2		$	2,811.9		$	2,794.5		$	—		$	2,807.5
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(228.0		)	(16,010.0		)	(11,268.3		)	(32,187.9		)	(48,197.9		)	59,694.2			—
Proceeds from sale of Oncology franchise	—			—			—			2,412.2			2,412.2			—			2,412.2
Purchases of PP&E	—			—			—			(564.6		)	(564.6		)	—			(564.6		)
Acquisition of business, net of cash acquired	—			—			—			(104.7		)	(104.7		)	—			(104.7		)
Proceeds from sale of investments	—			—			—			31.8			31.8			—			31.8
Other, net	—			—			—			(97.9		)	(97.9		)	—			(97.9		)
Net cash provided by/(used in) investing activities	(228.0		)	(16,010.0		)	(11,268.3		)	(30,511.1		)	(46,521.1		)	59,694.2			1,676.8
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	—			2,685.0			—			1,050.3			3,735.3			—			3,735.3
Repayment of revolving line of credit, long term and short term borrowings	—			(3,780.0		)	(3,129.5		)	(1,059.5		)	(4,839.5		)	—			(7,969.0		)
Proceeds from/(to) intercompany borrowings	923.5			17,122.4			14,142.0			27,506.3			44,628.7			(59,694.2		)	—
Contingent consideration payment	(396.0		)	—			—			—			—			—			(396.0		)
Payment of dividend	(48.6		)	—			—			(228.0		)	(228.0		)	—			(276.6		)
Proceeds from issuance of stock for share-based compensation arrangements	0.3			—			9.1			171.4			171.4			—			180.8
Other, net	—			—			(18.0		)	(7.6		)	(7.6		)	—			(25.6		)
Net cash provided by/(used in) financing activities	479.2			16,027.4			11,003.6			27,432.9			43,460.3			(59,694.2		)	(4,751.1		)
Effect of foreign exchange rate changes on cash and cash equivalents	—			—			—			(11.9		)	(11.9		)	—			(11.9		)
Net decrease in cash, cash equivalents and restricted cash	—			—			(0.5		)	(278.2		)	(278.2		)	—			(278.7		)
Cash, cash equivalents and restricted cash at beginning of period	—			—			0.5			511.3			511.3			—			511.8
Cash, cash equivalents and restricted cash at end of period	$	—		$	—		$	—		$	233.1		$	233.1		$	—		$	233.1



Condensed Consolidating Statements of Cash Flows
(Unaudited, In millions)
Nine months ended September 30, 2017	Shire plc (Parent Guarantor)			SAIIDAC (SAIIDAC Notes Subsidiary Issuer)			Baxalta Inc. (Baxalta Notes Subsidiary Issuer and SAIIDAC Notes Subsidiary Guarantor)			Non-Guarantor Non-Issuer Subsidiaries			Non-Guarantor Subsidiaries of Baxalta Notes			Eliminations			Consolidated
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided by/(used in) operating activities	$	(102.9	)	$	(62.9	)	$	0.6		$	2,902.3		$	2,839.4		$	—		$	2,737.1
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(1,339.3		)	(262.9		)	(659.3		)	(4,209.1		)	(4,472.0		)	6,470.6			—
Purchases of PP&E	—			—			—			(565.5		)	(565.5		)	—			(565.5		)
Proceeds/(payments) from sale of investments	—			—			(9.8		)	57.9			57.9			—			48.1
Other, net	—			—			—			34.8			34.8			—			34.8
Net cash provided by/(used in) investing activities	(1,339.3		)	(262.9		)	(669.1		)	(4,681.9		)	(4,944.8		)	6,470.6			(482.6		)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	2,110.0			1,150.0			—			1.6			1,151.6			—			3,261.6
Repayment of revolving line of credit, long term and short term borrowings	(2,560.0		)	(3,100.0		)	—			(4.5		)	(3,104.5		)	—			(5,664.5		)
Proceeds from/(to) intercompany borrowings	1,919.6			2,275.8			623.9			1,651.3			3,927.1			(6,470.6		)	—
Payment of dividend	(27.6		)	—			—			(207.1		)	(207.1		)	—			(234.7		)
Proceeds from issuance of stock for share-based compensation arrangements	0.2			—			4.6			87.4			87.4			—			92.2
Other, net	—			—			(0.8		)	(25.4		)	(25.4		)	—			(26.2		)
Net cash provided by/(used in) financing activities	1,442.2			325.8			627.7			1,503.3			1,829.1			(6,470.6		)	(2,571.6		)
Effect of foreign exchange rate changes on cash and cash equivalents	—			—			—			6.2			6.2			—			6.2
Net decrease in cash and cash equivalents and restricted cash	—			—			(40.8		)	(270.1		)	(270.1		)	—			(310.9		)
Cash, cash equivalents, and restricted cash at beginning of period	—			—			41.7			512.8			512.8			—			554.5
Cash, cash equivalents, and restricted cash at end of period	$	—		$	—		$	0.9		$	242.7		$	242.7		$	—		$	243.6